There's no question technology played a huge role in the recent/current
pandemic, including especially in the
https://a16z.com/2020/08/14/vaccines-vaccinology-renaissance-covid-
pandemic-beyond/" target="new">plug-and-
play engineering and incredibly fast development
https://future.a16z.com/podcasts/moderna-covid-vaccine-mrna-
technology/" target="new">behind the mRNA vaccines... But is there an even bigger role for the
private sector, not just government, to play (and partner) when it comes to
key infrastructure for future such emergencies, and even beyond?
Especially given how faulty the translation of institutional science to policy
and public health measures turned out to be -- for instance, with "6 feet" of
social distancing, or with fomite (vs. aerosol) transmission of COVID. And why
are we still talking about the same, not specific, vaccine booster for the
Delta variant? What can we learn about real-world evidence, other clinical
trial approaches, and progressive (vs. binary) EUA approvals when it comes to
public health emergencies? Are capabilities like genomic surveillance and
mapping strains -- which require layers of technology, real time -- sitting in
the right places?
In this special
book-launch episode of
the a16z Podcast, former FDA commissioner Dr. Scott Gottlieb -- author of the
upcoming
https://www.harpercollins.com/products/uncontrolled-
spread-scott-gottlieb" target="new">new book,
Uncontrolled Spread: Why COVID-19 Crushed Us, and How
We Can Defeat the Next Pandemic \-- shares insights on the above, and
revealing stories from behind the scenes. Do we need a new entity to manage
public health through a national security lens, and is the government capable?
Gottlieb debates this and other probing questions from a16z co-founder Marc
Andreessen (who famously wrote "
It's time to
build"); a16z bio general
partner Vineeta Agarwala MD, Phd (who has spoken about
https://a16z.com/2021/05/18/bio-eats-world-the-trials-of-clinical-
trials/" target="new">the trials of clinical
trials, practiced medicine during the pandemic, and more); and founding a16z
bio general partner Vijay Pande PhD (who, among other things, founded the
distributed computing project
https://a16z.com/2020/06/14
/folding-at-home-supercomputer-protein-dynamics/" target="new">Folding@Home which pivoted to COVID
proteins).
One thing's for sure -- with this COVID crisis, we're at an inflection point
between old and new technology -- whether it's in how we make vaccines, or how
we apply the fields of synthetic biology and genetic epidemiology in public
health response. So now's the time to look both backward, and forward, to
really change things...
Leer más
There's no question technology played a huge role in the recent/current
pandemic, including especially in the
https://a16z.com/2020/08/14/vaccines-vaccinology-renaissance-covid-
pandemic-beyond/" target="new">plug-and-
play engineering and incredibly fast development
https://future.a16z.com/podcasts/moderna-covid-vaccine-mrna-
technology/" target="new">behind the mRNA vaccines... But is there an even bigger role for the
private sector, not just government, to play (and partner) when it comes to
key infrastructure for future such emergencies, and even beyond?
Especially given how faulty the translation of institutional science to policy
and public health measures turned out to be -- for instance, with "6 feet" of
social distancing, or with fomite (vs. aerosol) transmission of COVID. And why
are we still talking about the same, not specific, vaccine booster for the
Delta variant? What can we learn about real-world evidence, other clinical
trial approaches, and progressive (vs. binary) EUA approvals when it comes to
public health emergencies? Are capabilities like genomic surveillance and
mapping strains -- which require layers of technology, real time -- sitting in
the right places?
In this special
book-launch episode of
the a16z Podcast, former FDA commissioner Dr. Scott Gottlieb -- author of the
upcoming
https://www.harpercollins.com/products/uncontrolled-
spread-scott-gottlieb" target="new">new book,
Uncontrolled Spread: Why COVID-19 Crushed Us, and How
We Can Defeat the Next Pandemic \-- shares insights on the above, and
revealing stories from behind the scenes. Do we need a new entity to manage
public health through a national security lens, and is the government capable?
Gottlieb debates this and other probing questions from a16z co-founder Marc
Andreessen (who famously wrote "
It's time to
build"); a16z bio general
partner Vineeta Agarwala MD, Phd (who has spoken about
https://a16z.com/2021/05/18/bio-eats-world-the-trials-of-clinical-
trials/" target="new">the trials of clinical
trials, practiced medicine during the pandemic, and more); and founding a16z
bio general partner Vijay Pande PhD (who, among other things, founded the
distributed computing project
https://a16z.com/2020/06/14
/folding-at-home-supercomputer-protein-dynamics/" target="new">Folding@Home which pivoted to COVID
proteins).
One thing's for sure -- with this COVID crisis, we're at an inflection point
between old and new technology -- whether it's in how we make vaccines, or how
we apply the fields of synthetic biology and genetic epidemiology in public
health response. So now's the time to look both backward, and forward, to
really change things...
Leer menos